Rapid Dose Therapeutics (RDT) Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Rapid Dose Therapeutics (RDT)'s estimated annual revenue is currently $2.4M per year.(i)
  • Rapid Dose Therapeutics (RDT)'s estimated revenue per employee is $201,000

Employee Data

  • Rapid Dose Therapeutics (RDT) has 12 Employees.(i)
  • Rapid Dose Therapeutics (RDT) grew their employee count by 0% last year.

Rapid Dose Therapeutics (RDT)'s People

NameTitleEmail/Phone
1
CEO and FounderReveal Email/Phone
2
Co-Founder, SVP Business DevelopmentReveal Email/Phone
3
Director Marketing CommunicationsReveal Email/Phone
4
Sales ExecutiveReveal Email/Phone
5
Quality Assurance and Scientific Research SpecialistReveal Email/Phone
6
Formulations Research TechnicianReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.7M58-37%N/AN/A
#2
$17.3M866%N/AN/A
#3
$43.8M21822%N/AN/A
#4
$7.6M38-3%N/AN/A
#5
$17.9M983%$192.2MN/A
#6
$59.1M294-9%N/AN/A
#7
$0.5M5-58%N/AN/A
#8
$8.2M41-41%N/AN/A
#9
$25.9M12929%N/AN/A
#10
$6.7M6763%N/AN/A
Add Company

What Is Rapid Dose Therapeutics (RDT)?

We are a Canadian publicly traded Canadian life-sciences company that provides innovation, proprietary drug delivery technologies designed to improve outcomes and quality of lives. RDT offers quick, convenient precise and discreet™ and smoke-free choices to consumers. RDT is focused on clinical research and product development for the healthcare manufacturing industry, including nutraceutical, pharmaceutical and cannabis industries. RDT is committed to innovative solutions for future market needs — including humans, animals and plants.\n\nWe are now publicly listed on the Canadian Securities Exchange: $DOSE.

keywords:N/A

N/A

Total Funding

12

Number of Employees

$2.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1M12-14%N/A
#2
$1M129%N/A
#3
$1M129%N/A
#4
$1.8M13-19%N/A
#5
$1.2M1330%N/A